Julie Rytlewski

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma

Timothy F. Cloughesy, Aaron Mochizuki, Joey Orpilla et al. · Nature Medicine · 2019 · 1.3K citations

Neuro-oncology, Neoadjuvant Anti-pd-1 Immunotherapy, Tumor Immunology +14

Innate Immune Landscape in Early Lung Adenocarcinoma by Paired Single-Cell Analyses

Yonit Lavin, Soma Kobayashi, Andrew M. Leader et al. · Cell · 2017 · 1.2K citations · Full text

Cancer Immunosurveillance, Paired Single-cell Analyses, Single Cell Sequencing +11

ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial

John Wrangle, Vamsidhar Velcheti, Manish R. Patel et al. · The Lancet Oncology · 2018 · 410 citations

Il-15 Superagonist, Medicine, Immunology +8

T cell receptor repertoire features associated with survival in immunotherapy-treated pancreatic ductal adenocarcinoma

Alexander C. Hopkins, Mark Yarchoan, Jennifer N. Durham et al. · JCI Insight · 2018 · 225 citations · Full text

The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma

David Agdashian, Mei ElGindi, Changqing Xie et al. · Cancer Immunology Immunotherapy · 2019 · 168 citations · Full text

Cancer Immunosurveillance, Hepatology, Intra-tumoral T Cells +9